Phase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation

This study is testing an experimental drug called CX-5461 to see if it can safely stop the growth of certain solid tumors. Researchers want to find the best dose to help patients whose cancers have specific genetic mutations, which may help identify more effective treatment options for the future.

This trial is for adults with breast, prostate, ovarian, or pancreatic cancer who have specific genetic mutations in their cancer, such as BRCA or PALB2. You must be in generally stable health and have recovered from the side effects of any previous cancer treatments.

Participants will receive the experimental drug through an IV infusion on specific days during a 28-day cycle. Doctors will monitor you closely to track how your cancer responds, how you feel, and if you experience any side effects.

This study is currently recruiting patients at locations in Santa Monica, California; Tampa, Florida; and Boston, Massachusetts. Please speak with your doctor or the study team to see if one of these centers is the right fit for your care.